MAIT cells: Partners or enemies in cancer immunotherapy?

30Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

A recent boom in mucosal-associated invariant T (MAIT) cell research has identified relationships between MAIT cell abundance, function, and clinical outcomes in various malignancies. As they express a variety of immune checkpoint receptors and ligands, and possess strong cytotoxic functions, MAIT cells are an attractive new subject in the field of tumor immunology. MAIT cells are a class of innate-like T cells that express a semi-invariant T cell antigen receptor (TCR) that recognizes microbially derived non-peptide antigens presented by the non-polymorphic MHC class-1 like molecule, MR1. In this review, we outline the current (and often contradictory) evidence exploring MAIT cell biology and how MAIT cells impact clinical outcomes in different human cancers, as well as what role they may have in cancer immunotherapy.

Cite

CITATION STYLE

APA

Cogswell, D. T., Gapin, L., Tobin, H. M., McCarter, M. D., & Tobin, R. P. (2021, April 1). MAIT cells: Partners or enemies in cancer immunotherapy? Cancers. MDPI AG. https://doi.org/10.3390/cancers13071502

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free